Bayer Aktiengesellschaft (WSE:BAY)
Poland · Delayed Price · Currency is PLN | Market Cap | 151.61B +44.4% |
| Revenue (ttm) | 194.35B -2.9% |
| Net Income | -9.26B |
| EPS | -9.43 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 8.12 |
| Dividend | 0.47 (0.30%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 33 |
| Open | 153.95 |
| Previous Close | 153.10 |
| Day's Range | 153.10 - 153.95 |
| 52-Week Range | 108.66 - 198.18 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer price target raised to EUR 40.50 from EUR 40 at Berenberg
Berenberg analyst Sebastian Bray raised the firm’s price target on Bayer (BAYRY) to EUR 40.50 from EUR 40 and keeps a Hold rating on the shares.
Bayer Receives FDA Approval For AMBELVIST For Contrast-Enhanced MRI
(RTTNews) - Bayer AG (BARY) today received U.S. FDA approval for AMBELVIST, a next-generation gadolinium -based contrast agent designed to help clinicians detect and visualize lesions with abnormal va...
Bayer announces FDA approval for Ambelvist
Bayer (BAYRY) announced that the FDA approved Ambelvist, a new, intravenous macrocyclic gadolinium-based contrast agent indicated for contrast-enhanced magnetic resonance imaging to detect and visuali...
Bayer's MRI Contrast Agent Ambelvist Wins FDA Approval
LEVERKUSEN (dpa-AFX) - Bayer AG (BYR.L) said on Monday that the U.S. Food and Drug Administration approved Ambelvist, a new intravenous macrocyclic gadolinium-based contrast agent for use in contr...
Bayer's AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) approved AMBELVIST® (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contras...
Bayer’s AMBELVIST (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions
Bayer today announced that the U.S. Food and Drug Administration (FDA) approved AMBELVIST (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) indicated for cont...
5 Marketer Moves to Know This Week: Knix, Bayer, and More
A weekly roundup of the biggest U.S. and global marketing leadership appointments.
Bayer hopes to speed up biofuel feedstock plan amid Iran war energy crunch
Bayer is hoping to speed up a plan to facilitate North American production of biofuel feedstocks like camelina in the wake of the Iran war, the drug-making and crop science giant said on Wednesday.
Bayer appoints Reinhard as President of the Radiology business
Bayer (BAYRY) announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer’s Pharmaceuticals Division, effective August 1, 2026. In his new capacity, he will re...
Dr. Jost Reinhard Appointed President of Bayer's Radiology Business
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer's Pharmaceuticals Division, effective August 1, 2026. ...
Bayer announces leadership changes within Consumer Health division
Bayer (BAYRY) announced leadership changes within its Consumer Health division. Key leadership appointments include: Samantha Avivi appointed global Chief Marketing Officer, Consumer Health; Analia de...
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth
BASEL, Switzerland & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further en...
Bayer says Kerendia met primary endpoint in Phase III FIND-CKD trial
Bayer (BAYRY) announced full results from the Phase III FIND-CKD trial investigating Kerendia in adults with non-diabetic chronic kidney disease who were also receiving background standard of care. In...
Phase III FIND‑CKD Results Show Bayer's KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adults with non-diabetic chronic kidney dise...
Phase III FIND‑CKD Results Show Bayer’s KERENDIA (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
Bayer Summary Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA (finerenone) in adults with non-diabetic chronic kidney disease (nd-CKD) who were also receivi...
Bayer (BAYRY) Confirms No Plans to Spin Off Monsanto Amid Roundup Lawsuits
Bayer (BAYRY) Confirms No Plans to Spin Off Monsanto Amid Roundup Lawsuits
Bayer Faces Legal Challenges Over Roundup, No Plans to Spin Off Monsanto
Bayer Faces Legal Challenges Over Roundup, No Plans to Spin Off Monsanto
Bayer says no plans to restructure despite litigation threat
Bayer has no plans to spin off Monsanto, a representative said on Tuesday, even as the company faces an avalanche of lawsuits over its Roundup weedkiller.
Bayer (BAYRY) Faces Legal Setback, Shares Drop Amid Settlement Uncertainty
Bayer (BAYRY) Faces Legal Setback, Shares Drop Amid Settlement Uncertainty
Bayer announces new investigational data from Kerendia’s Phase III trial
Bayer (BAYRY) announced that new investigational data from Kerendia’s Phase III clinical trial program will be presented in scientific sessions at the 63rd European Renal Association, ERA, Congress ta...
Bayer to Present First Full FIND-CKD Results Investigating KERENDIA (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
Presentations also include the INFINITY pooled analysis of KERENDIA (finerenone) across diabetic and non-diabetic chronic kidney disease. Bayer Summary Bayer today announced that new investigation...
Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that new investigational data from KERENDIA's Phase III clinical trial program will be presented in scientific sessions at the 63rd...
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
WHIPPANY, N.J.--(BUSINESS WIRE)--Primary results from the Phase II ARACOG (AFT-47) trial, a head-to-head randomized trial conducted by Alliance Foundation Trials LLC, showed that patients treated with...
ASCO 2026: Bayer Shares New Findings for NUBEQA (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
Primary results from the Phase II ARACOG (AFT-47) trial, a head-to-head randomized trial conducted by Alliance Foundation Trials LLC, showed that patients treated with NUBEQA (darolutamide; n=55) expe...
Bayer assumed with a Hold at Jefferies
Jefferies analyst Michael Leuchten assumed coverage of Bayer (BAYRY) with a Hold rating and a price target of EUR 40, up from EUR 25. Litigation resolution remains the main pivot,…